Donor-Specific HLA Antibodies Are Associated with Graft Failure and Delayed Hematologic Recovery after Unrelated Donor Hematopoietic Cell Transplantation

被引:9
作者
Martins Lima, Alberto Cardoso [1 ,2 ]
Getz, Joselito [1 ]
do Amaral, Geovana Borsato [1 ]
Loth, Gisele [3 ,4 ]
Moreira Funke, Vaneuza Araujo [3 ]
Nabhan, Samir Kanaan [3 ]
Petterle, Ricardo Rasmussen [5 ]
de Marco, Renato [2 ]
Gerbase-DeLima, Maria [2 ]
Pereira, Noemi Farah [1 ]
Bon, Carmem [3 ,4 ]
Pasquini, Ricardo [3 ]
机构
[1] Univ Fed Parana, Complexo Hosp Clin, Histocompatibil Lab, Rua Padre Camargo,280 1o Andar, BR-80060240 Curitiba, PR, Brazil
[2] Assoc Fundo Incent Pesquisa AFIP, Immunogenet Inst Igen, Sao Paulo, SP, Brazil
[3] Univ Fed Parana, Complexo Hosp Clin, Bone Marrow Transplantat Unit, Curitiba, PR, Brazil
[4] Hosp Pequeno Principe, Inst Pesquisa Pele Pequeno Principe, Curitiba, PR, Brazil
[5] Univ Fed Parana, Dept Integrat Med, Curitiba, PR, Brazil
来源
TRANSPLANTATION AND CELLULAR THERAPY | 2023年 / 29卷 / 08期
关键词
Donor-specific anti-HLA; antibodies; Unrelated donor transplantation; Graft failure; Delayed hematologic recovery; ALLOANTIBODIES; REJECTION; STRENGTH;
D O I
10.1016/j.jtct.2023.05.014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Graft failure (GF) is one of the major concerns after allogeneic hematopoietic cell transplantation (allo-HCT) and remains a significant cause of morbidity and mortality. Although previous reports have associated the presence of donor-specific HLA antibodies (DSAs) with an increased risk of GF after unrelated donor allo-HCT, recent studies have failed to confirm this association. We sought to validate the presence of DSAs as a risk factor for GF and hematologic recovery in the unrelated donor allo-HCT setting. We retrospectively evaluated 303 consecutive patients who under-went their first unrelated donor allo-HCT at our institution between January 2008 and December 2017. DSA evaluation was performed using 2 single antigen bead (SAB) assays; DSA titration with 1:2, 1:8, and 1:32 dilutions; C1q-binding assay; and absorption/elution protocol to assess possible false-positive DSA reactivity. The primary endpoints were neutrophil and platelet recovery and GF, and the secondary endpoint was overall survival. Multivariable analyses were performed using Fine-Gray competing risks regression and Cox proportional hazards regression models. The median patient age was 14 years (range, 0 to 61 years), 56.1% were male, and 52.5% underwent allo-HCT for nonmalig-nant disease, Eleven patients (3.63%) were DSA-positive, including 10 with preexisting DSAs and 1 with post-trans-plantation de novo DSAs. Nine patients had 1 DSA, 1 patient had 2 DSAs, and 1 patient had 3 DSAs, with a median mean fluorescent intensity (MFI) of 4334 (range, 588 to 20,456) and 3581 (range, 227 to 12,266) in LABScreen and LIFECODES SAB assays, respectively. Overall, 21 patients experienced GF, including 12 with primary graft rejection, 8 with secondary graft rejection, and 1 with primary poor graft function. The cumulative incidence of GF was 4.0% (95% confidence interval [CI], 2.2% to 6.6%) at 28 days, 6.6% (95% CI, 4.2% to 9.8%) at 100 days, and 6.9% (95% CI, 4.4% to 10.2%) at 365 days. In the multivariable analyses, DSA-positive patients had significantly delayed neutrophil recovery (subdistribution hazard ratio [SHR], .48; 95% CI, .29 to .81; P = .006) and platelet recovery (SHR, .51; 95% CI, .35 to .74; P = .0003) compared to patients without DSAs. In addition, only DSAs were significant predictors of primary GF at 28 days (SHR, 2.78; 95% CI, 1.65 to 4.68; P = .0001). The Fine-Gray regression also demonstrated that the presence of DSAs was strongly associated with a higher incidence of overall GF (SHR, 7.60; 95% CI, 2.61 to 22.14; P = .0002). DSA-positive patients with GF had significantly higher median MFI values than DSA-positive patients who achieved engraft-ment in the LIFECODES SAB assay using neat serum (10,334 versus 1250; P = .006) and in the LABScreen SAB at 1:32 dilution (1627 versus 61; P = .006). All 3 patients with C1q-positive DSAs failed to engraft. DSAs were not predictive of inferior survival (HR, .50; 95% CI, .20 to 1.26; P = .14). Our results validate the presence of DSAs as a significant risk factor for GF and delayed hematologic recovery after unrelated donor allo-HCT. Careful pretransplantation DSA evalua-tion may optimize unrelated donor selection and improve allo-HCT outcomes.& COPY; 2023 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:493.e1 / 493.e10
页数:10
相关论文
共 50 条
[41]   Donor-Specific Antibodies' Meaningful Impact on Liver Transplantation [J].
Aday, Ariel W. ;
O'Leary, Jacqueline G. .
LIVER TRANSPLANTATION, 2018, 24 (08) :999-1000
[42]   Reassessment of the clinical impact of preformed donor-specific anti-HLA-Cw antibodies in kidney transplantation [J].
Visentin, Jonathan ;
Bachelet, Thomas ;
Aubert, Olivier ;
Del Bello, Arnaud ;
Martinez, Charlie ;
Jambon, Frederic ;
Guidicelli, Gwendaline ;
Ralazamahaleo, Mamy ;
Bouthemy, Charlene ;
Cargou, Marine ;
Congy-Jolivet, Nicolas ;
Nong, Thoa ;
Lee, Jar-How ;
Sberro-Soussan, Rebecca ;
Couzi, Lionel ;
Kamar, Nassim ;
Legendre, Christophe ;
Merville, Pierre ;
Taupin, Jean-Luc .
AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 (05) :1365-1374
[43]   Desensitization for renal transplantation: depletion of donor-specific anti-HLA antibodies, preservation of memory antibodies, and clinical risks [J].
Rogers, Natasha M. ;
Eng, Hooi S. ;
Yu, Raymond ;
Kireta, Svjetlana ;
Tsiopelas, Eleni ;
Bennett, Greg D. ;
Brook, Nicholas R. ;
Gillis, David ;
Russ, Graeme R. ;
Coates, P. Toby .
TRANSPLANT INTERNATIONAL, 2011, 24 (01) :21-29
[44]   Donor specific antibodies after transplantation [J].
Platt, Jeffrey L. ;
Cascalho, Marilia .
PEDIATRIC TRANSPLANTATION, 2011, 15 (07) :686-690
[45]   Differential effects of donor-specific HLA antibodies in living versus deceased donor transplant [J].
Kamburova, E. G. ;
Wisse, B. W. ;
Joosten, I. ;
Allebes, W. A. ;
van der Meer, A. ;
Hilbrands, L. B. ;
Baas, M. C. ;
Spierings, E. ;
Hack, C. E. ;
van Reekum, F. E. ;
van Zuilen, A. D. ;
Verhaar, M. C. ;
Bots, M. L. ;
Drop, A. C. A. D. ;
Plaisier, L. ;
Seelen, M. A. J. ;
Sanders, J. S. F. ;
Hepkema, B. G. ;
Lambeck, A. J. A. ;
Bungener, L. B. ;
Roozendaal, C. ;
Tilanus, M. G. J. ;
Voorter, C. E. ;
Wieten, L. ;
van Duijnhoven, E. M. ;
Gelens, M. ;
Christiaans, M. H. L. ;
van Ittersum, F. J. ;
Nurmohamed, S. A. ;
Lardy, N. M. ;
Swelsen, W. ;
van der Pant, K. A. ;
van der Weerd, N. C. ;
ten Berge, I. J. M. ;
Bemelman, F. J. ;
Hoitsma, A. ;
van der Boog, P. J. M. ;
de Fijter, J. W. ;
Betjes, M. G. H. ;
Heidt, S. ;
Roelen, D. L. ;
Claas, F. H. ;
Otten, H. G. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 (09) :2274-2284
[46]   Treatment of Anti-HLA Donor-Specific Antibodies Results in Increased Infectious Complications and Impairs Survival after Liver Transplantation [J].
Unlu, Sinem ;
Lachmann, Nils ;
Jara, Maximilian ;
Ritschl, Paul Viktor ;
Wiering, Leke ;
Eurich, Dennis ;
Denecke, Christian ;
Biebl, Matthias ;
Chopra, Sascha ;
Gul-Klein, Safak ;
Schoning, Wenzel ;
Schmelzle, Moritz ;
Reinke, Petra ;
Tacke, Frank ;
Pratschke, Johann ;
Ollinger, Robert ;
Dziodzio, Tomasz .
JOURNAL OF CLINICAL MEDICINE, 2020, 9 (12)
[47]   Risk factors for the development of donor-specific antibodies after pediatric heart transplantation [J].
Godown, Justin ;
Slaughter, James C. ;
Fossey, Sallyanne C. ;
McKane, Meghann ;
Dodd, Debra A. .
PEDIATRIC TRANSPLANTATION, 2015, 19 (08) :906-910
[48]   Donor-Specific Antibodies Against Donor Human Leukocyte Antigen are Associated with Graft Inflammation but Not with Fibrosis Long-Term After Liver Transplantation: An Analysis of Protocol Biopsies [J].
Guel-Klein, Safak ;
Hegermann, Henriette ;
Roehle, Robert ;
Schmelzle, Moritz ;
Tacke, Frank ;
Schoening, Wenzel ;
Oellinger, Robert ;
Dziodzio, Tomasz ;
Maier, Patrick ;
Plewe, Julius M. ;
Horst, David ;
Sauer, Igor Maximilian ;
Pratschke, Johann ;
Lachmann, Nils ;
Eurich, Dennis .
JOURNAL OF INFLAMMATION RESEARCH, 2021, 14 :2697-2712
[49]   Preformed donor-specific antibodies are associated with 90-day mortality in living-donor liver transplantation [J].
Tamura, Kei ;
Tohyama, Taiji ;
Watanabe, Jota ;
Nakamura, Taro ;
Ueno, Yoshitomo ;
Inoue, Hitoshi ;
Honjo, Masahiko ;
Sakamoto, Katsunori ;
Takai, Akihiro ;
Ogawa, Kohei ;
Takada, Yasutsugu .
HEPATOLOGY RESEARCH, 2019, 49 (08) :929-941
[50]   Posttransplant Donor-Specific Anti-HLA Antibodies Negatively Impact Pancreas Transplantation Outcome [J].
Cantarovich, D. ;
De Amicis, S. ;
Akl, A. ;
Devys, A. ;
Vistoli, F. ;
Karam, G. ;
Soulillou, J. -P. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 (12) :2737-2746